Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects

Franke, Andreas; Bagusat, Christiana; Rust, Sebastian; Engel, Alice; Lieb, Klaus
November 2014
European Archives of Psychiatry & Clinical Neuroscience;Nov2014 Supplement, Vol. 264, p83
Academic Journal
Pharmacological 'cognitive enhancement' (CE) is defined as the use of any psychoactive drug with the purpose of enhancing cognition, e.g. regarding attention, concentration or memory by healthy subjects. Substances commonly used as CE drugs can be categorized into three groups of drugs: (1) over-the-counter (OTC) drugs such as coffee, caffeinated drinks/energy drinks, caffeine tablets or Ginkgo biloba; (2) drugs being approved for the treatment of certain disorders and being misused for CE: drugs to treat attention-deficit/hyperactivity disorder (ADHD) such as the stimulants methylphenidate (MPH, e.g. Ritalin) or amphetamines (AMPH, e.g. Attentin or Adderall), to treat sleep disorders such as modafinil or to treat Alzheimer's disease such as acetylcholinesterase inhibitors; (3) illicit drugs such as illicit AMPH, e.g. 'speed', ecstasy, methamphetamine (crystal meth) or others. Evidence from randomized placebo-controlled trials shows that the abovementioned substances have limited pro-cognitive effects as demonstrated, e.g. regarding increased attention, increased cognitive speed or shortening of reaction times, but on the same time poses considerable safety risks on the consumers. Prevalence rates for the use of CE drugs among healthy subjects show a broad range from less than 1 % up to more than 20 %. The range in prevalence rates estimates results from several factors which are chosen differently in the available survey studies: type of subjects (students, pupils, special professions, etc.), degree of anonymity in the survey (online, face-to-face, etc.), definition of CE and substances used/misused for CE, which are assessed (OTC drugs, prescription, illicit drugs) as well as time periods of use (e.g. ever, during the past year/month/week, etc.). A clear and comprehensive picture of the drugs used for CE by healthy subjects and their adverse events and safety risks as well as comprehensive and comparable international data on the prevalence rates of CE among healthy subjects are of paramount importance for informing policy makers and healthcare professionals about CE.


Related Articles

  • The Incidence, Nature and Consequences of Adverse Events in Iranian Hospitals. Sari, Ali Akbari; Doshmangir, Leila; Torabi, Fereshteh; Rashidian, Arash; Sedaghat, Mojtaba; Ghomi, Robabeh; Prasopa-plaizier, Nittita // Archives of Iranian Medicine (AIM);Dec2015, Vol. 18 Issue 12, p811 

    Introduction: Adverse events are relatively common in healthcare, leading to extensive harm to patients and a significant drain on healthcare resources. Identifying the extent, nature and consequences of adverse events is an important step in preventing adverse events and their consequences...

  • Hypoglycemia and Glycemic Control in Type 1 Diabetes: a Meta-analysis of Five Randomized Controlled Trials Comparing NPH Insulin with Insulin Glargine. Mullins, Peter; Jarvinen, Hannele Yki; Sharplin, Peter A.; Riddle, Matthew // Diabetes;Jun2007 Supplement 1, Vol. 56, pA575 

    Patient-level data from five randomized clinical trials comparing insulin NPH and insulin glargine, including 1,899 patients diagnosed with type 1 diabetes, were used to evaluate the relationship between hypoglycemia and HbA1c. The analysis uses a negative binomial regression which applies...

  • Synergistic effect of combined transcranial direct current stimulation/constraint-induced movement therapy in children and young adults with hemiparesis: study protocol. Gillick, Bernadette; Menk, Jeremiah; Mueller, Bryon; Meekins, Gregg; Krach, Linda E.; Feyma, Timothy; Rudser, Kyle // BMC Pediatrics;11/12/2015, Vol. 15, p1 

    Background: Perinatal stroke occurs in more than 1 in 2,500 live births and resultant congenital hemiparesis necessitates investigation into interventions which may improve long-term function and decreased burden of care beyond current therapies (...

  • Research and Clinical Trials.  // Mayo Clinic Guide to Living with a Spinal Cord Injury: Moving Ah;2009, p211 

    The article offers information on research and clinical trials, and benefits and risk of research studies. It mentions that the U.S. Food and Drug Administration (FDA) is committed to protect people in participating trials in the country and the clinical research trials are registered at...

  • Taking the Negative View of Current Migraine Treatments. Tfelt-Hansen, Peer; Olesen, Jes // CNS Drugs;2012, Vol. 26 Issue 5, p375 

    Acute migraine treatment is given to abolish ongoing attacks, while pro- phylactic migraine treatment is given on a daily basis to prevent the occurrence of migraine attacks as far as possible. The majority of migraine patients do not use the specific acute anti-migraine drugs, the triptans....

  • Sequential Adjuvant Chemotherapy and Radiotherapy in Treatment of Early Stage Endometrial Carcinoma: Single Institutional Experience. Tunio, Mutahir; Asiri, Mushabbab Al; Alhadab, Abdul Rehman; Bayoumi, Yasser; Alsaeed, Eyad; Riaz, Khalid; Amro, Abdullah; Ismail, Abdel; AlObaid, Abdel Aziz // Journal of Nuclear Medicine & Radiation Therapy;2012 Supplement 6, p1 

    Background: Aim was to evaluate the additional benefit of adjuvant chemotherapy in patients of early stage endometrial carcinoma (EC) with adverse features. Materials and methods: Between June 2006 and July 2011, 56 patients with EC after surgery were randomized to receive either adjuvant...

  • PRIMER. Evaluating equivalence and noninferiority trials. Dasgupta, Anandaroop; Lawson, Kenneth A.; Wilson, James P. // American Journal of Health-System Pharmacy;8/15/2010, Vol. 67 Issue 16, p1337 

    Purpose. The conceptual issues related to the design of equivalence and noninferiority trials and considerations for interpreting the findings of such trials are described. Summary. Comparative effectiveness research (CER) has recently gained importance in the evaluation of different treatment...

  • Whole Animal Experiments Should Be More Like Human Randomized Controlled Trials. Muhlhausler, Beverly S.; Bloomfield, Frank H.; Gillman, Matthew W. // PLoS Biology;Feb2013, Vol. 11 Issue 2, p1 

    The authors discuss the improvement and revision of the "Animal Research: Reporting In Vivo Experiments" (ARRIVE) guidelines for the conduct and scientific reporting of animal experiments in 2010. They are critical that the guidelines could enhance overall quality of the experiments and its...

  • Intermediate results of a prospective randomized controlled trial of traditional four-port laparoscopic cholecystectomy versus single-incision laparoscopic cholecystectomy. Phillips, Melissa; Marks, Jeffrey; Roberts, Kurt; Tacchino, Roberto; Onders, Raymond; DeNoto, George; Rivas, Homero; Islam, Arsalla; Soper, Nathaniel; Gecelter, Gary; Rubach, Eugene; Paraskeva, Paraskevas; Shah, Sajani // Surgical Endoscopy;May2012, Vol. 26 Issue 5, p1296 

    Background: Minimally invasive techniques have become an integral part of general surgery, with recent investigation into single-incision laparoscopic cholecystectomy (SILC). This study presents a prospective, randomized, multicenter, single-blind trial of SILC compared with four-port...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics